Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Schutt

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 23, 2016
Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's DiseaseKatherine E Olson, Aditya N Bade, Charles R Schutt, et al.
Journal of Virology|August 1, 2024
Age-dependent Powassan virus lethality is linked to glial cell activation and divergent neuroinflammatory cytokine responses in a murine modelMegan C Mladinich, Grace E Himmler, Jonas N Conde, et al.
Journal of Virology|October 13, 2021
Powassan Viruses Spread Cell to Cell during Direct Isolation from <i>Ixodes</i> Ticks and Persistently Infect Human Brain Endothelial Cells and PericytesJonas N Conde, Santiago Sanchez-Vicente, Nicholas Saladino, et al.
Mbio|November 1, 2018
Combinatorial Loss of the Enzymatic Activities of Viral Uracil-DNA Glycosylase and Viral dUTPase Impairs Murine Gammaherpesvirus Pathogenesis and Leads to Increased Recombination-Based Deletion in the Viral GenomeQiwen Dong, Kyle R Smith, Darby G Oldenburg, et al.
Mbio|July 25, 2023
Establishment of a CPER reverse genetics system for Powassan virus defines attenuating NS1 glycosylation sites and an infectious NS1-GFP11 reporter virusJonas N Conde, Grace E Himmler, Megan C Mladinich, et al.
NPJ Parkinson'S Disease|June 27, 2017
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trialHoward E Gendelman, Yuning Zhang, Pamela Santamaria, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 23, 2016
Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's DiseaseKatherine E Olson, Aditya N Bade, Charles R Schutt, et al.
Journal of Virology|August 1, 2024
Age-dependent Powassan virus lethality is linked to glial cell activation and divergent neuroinflammatory cytokine responses in a murine modelMegan C Mladinich, Grace E Himmler, Jonas N Conde, et al.
Journal of Virology|October 13, 2021
Powassan Viruses Spread Cell to Cell during Direct Isolation from <i>Ixodes</i> Ticks and Persistently Infect Human Brain Endothelial Cells and PericytesJonas N Conde, Santiago Sanchez-Vicente, Nicholas Saladino, et al.
Mbio|November 1, 2018
Combinatorial Loss of the Enzymatic Activities of Viral Uracil-DNA Glycosylase and Viral dUTPase Impairs Murine Gammaherpesvirus Pathogenesis and Leads to Increased Recombination-Based Deletion in the Viral GenomeQiwen Dong, Kyle R Smith, Darby G Oldenburg, et al.
Mbio|July 25, 2023
Establishment of a CPER reverse genetics system for Powassan virus defines attenuating NS1 glycosylation sites and an infectious NS1-GFP11 reporter virusJonas N Conde, Grace E Himmler, Megan C Mladinich, et al.
NPJ Parkinson'S Disease|June 27, 2017
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trialHoward E Gendelman, Yuning Zhang, Pamela Santamaria, et al.
Pageof 3